Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00778713 · ClinicalTrials.gov registry record · NA
Bioequivalence Study of Fosinopril Sodium / Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fed Conditions
A NA study, sponsored by Ranbaxy Laboratories Limited.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT00778713: Completed NA study, sponsored by Ranbaxy Laboratories Limited.
NCT00778713 is a NA study that has completed, run by Ranbaxy Laboratories Limited. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00778713, a NA study, has completed, sponsored by Ranbaxy Laboratories Limited.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
The objective of this study is to compare the relative bioavailability of Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets of Ranbaxy laboratories Limited with that of Monopril ® - HCT 20-12.5 mg tablets by Bristol Meyers Squibb following a single oral dose (1 x 20/12.5 mg tablet) in healthy adult subjects under non-fasting conditions.
Interventions
- DRUG Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2003-03 |
| Est. Completion | 2003-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00778713
The ClinicalTrials.gov registry entry for NCT00778713 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ranbaxy Laboratories Limited, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets is the first listed.
NCT00778713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00778713 about?
NCT00778713 is a clinical study titled "Bioequivalence Study of Fosinopril Sodium / Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fed Conditions". The objective of this study is to compare the relative bioavailability of Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets of Ranbaxy laboratories Limited with that of Monopril ® - HCT 20-12.5 mg tablets by Bristol Meyers Squibb following a single oral dose (1 x 20/12.5 mg tablet) in hea...
What is the current status of trial NCT00778713?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2003-03. Estimated completion is 2003-04.
What interventions are being tested in trial NCT00778713?
The interventions under investigation include: Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets (DRUG).
Who is sponsoring clinical trial NCT00778713?
This trial is sponsored by Ranbaxy Laboratories Limited, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.